J. Carey

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial

E. Kimby, A. Pettitt, A. Schuh, 2015, The Lancet.

Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial

T. Robak, K. Kuliczkowski, K. Warzocha, 2017, Leukemia & lymphoma.

Assessment of the effect of ofatumumab on cardiac repolarization

C. Hottenstein, G. Chan, Eric Lewis, 2015, Journal of clinical pharmacology.

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial

P. Sonneveld, A. Chanan-Khan, A. Nooka, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.

L. Staudt, W. Wilson, L. Sehn, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911)

E. Kimby, A. Schuh, T. Robak, 2013 .

Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial

H. Goldschmidt, M. Dimopoulos, P. Richardson, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with newly diagnosed multiple myeloma (NDMM) for whom transplant is not planned as initial therapy: A multicenter, randomized, phase III study (CEPHEUS).

T. Facon, J. Vermeulen, S. Usmani, 2019, Journal of Clinical Oncology.

Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B‐cell lymphoma in the phase III clinical trial of R‐CHOP ± ibrutinib

L. Staudt, W. Wilson, L. Sehn, 2021, British journal of haematology.

A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

L. Staudt, W. Wilson, L. Sehn, 2018, Blood.